Cardiovascular events like a heart attack are more likely in people with ANCA-associated vasculitis (AAV) who also have diabetes, a study reported. Other identified risk factors for AAV patients, a group known to be at cardiovascular disease risk, included older age and a prior history of cardiovascular problems. “Treatment…
Preventive, or prophylactic treatment with certain antibiotics can reduce the risk of severe infections for people with ANCA-associated vasculitis (AAV) who are receiving immunosuppressive treatment, a new analysis shows. Specifically, good results were found in a clinical trial with a combination of antibiotics known as TMP/SMX. “This … is…
Measuring the number of immune T-cells in urine could be used to help identify kidney damage in people with ANCA-associated vasculitis (AAV), a new study suggests. These urinary T-cells also may aid in predicting treatment responses and the risk of future disease relapse. “Their promising potential as noninvasive…
Higher blood levels of the molecule pro-calcitonin (PCT) are a marker of lung infection among ANCA-associated vasculitis (AAV) patients with lung disease, a new study reports. Combining PCT with other blood markers can further increase the accuracy of identifying infection, and may be useful for distinguishing between AAV-related lung…
Over the past year, ANCA Vasculitis News has brought you coverage of the latest developments in research related to ANCA-associated vasculitis (AAV). We look forward to continuing to bring you news about advances in research and treatment in the new year. Here we have compiled a list of the top…
Hepatitis E infection can be effectively managed in people with ANCA-associated vasculitis (AAV) by pausing immunosuppressive therapy, though patients may experience AAV flares during this pause, a new study shows. “Despite potent immunosuppression before infection, all patients cleared the virus after cessation of the immunosuppressant without additional anti-viral therapy.
People with ANCA-associated vasculitis (AAV) are at an increased risk of experiencing cardiovascular problems, such as a stroke, according to a new study done in South Korea. Indeed, AAV patients were found to have a more than two times higher risk of cardiovascular health problems than individuals without any…
Two cases of teen boys with ANCA-associated vasculitis (AAV) that caused heart problems — a very rare manifestation of the autoimmune disease — were described in a recent report. AAV-related heart issues may contribute to serious health concerns such as stroke, so it is important to screen for these…
After approximately $3.7 billion in acquisitions, Amgen will own the rights to Tavneos (avacopan), an approved oral therapy developed by ChemoCentryx to treat ANCA-associated vasculitis (AAV). Amgen is acquiring ChemoCentryx in a cash deal, expected to be completed by year’s end, the companies announced. “The acquisition of ChemoCentryx represents a…
Measuring the blood levels of a protein called BAFF could help predict the chances of remission after induction treatment with rituximab in people with ANCA vasculitis (AAV), according to a new study. Determining the BAFF levels in the blood also could guide further care for AAV patients, the researchers…
Get regular updates to your inbox.